Linatab M 2.5 mg + 1000 mg is a combination oral therapy designed for adults with type 2 diabetes mellitus. This formulation combines Linagliptin, a DPP-4 inhibitor, with Metformin Hydrochloride, a widely used biguanide, to provide enhanced glycemic control. The dual mechanism targets both insulin secretion and glucose production, making it effective for patients who cannot achieve adequate control with diet, exercise, or monotherapy alone.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

• Linagliptin: Dipeptidyl Peptidase-4 (DPP-4) inhibitor

• Metformin Hydrochloride: Biguanide antidiabetic agent

Pharmacology

The combination works via two complementary mechanisms:

1. Linagliptin (2.5 mg): Inhibits DPP-4, preventing the breakdown of incretin hormones GLP-1 and GIP. This:

   • Stimulates glucose-dependent insulin secretion from pancreatic beta cells

   • Suppresses glucagon secretion from pancreatic alpha cells

2. Metformin Hydrochloride (1000 mg): Reduces hepatic glucose production and increases insulin sensitivity in peripheral tissues. This combination reduces postprandial and fasting blood glucose levels effectively.

Indications

Linatab M is indicated for:

• Adults with type 2 diabetes mellitus inadequately controlled by diet and exercise

• Patients who require dual therapy for improved glycemic control

• Those who cannot use Metformin alone due to insufficient control or need enhanced therapy

Dosage and Administration

• Adults: Take one tablet once or twice daily, preferably with meals to reduce gastrointestinal side effects.

• Renal Impairment: Linagliptin does not require dose adjustment, but Metformin dose must be monitored in patients with renal dysfunction.

• Combination Therapy: Linatab M may be used along with other antidiabetic agents under medical supervision.

Contraindications

• Hypersensitivity to Linagliptin, Metformin, or any excipients

• Severe renal impairment, acute or chronic metabolic acidosis, including diabetic ketoacidosis

Side Effects

Linatab M is generally well tolerated. Common side effects may include:

• Gastrointestinal disturbances: nausea, vomiting, diarrhea, abdominal discomfort

• Hypoglycemia (especially when used with sulfonylureas or insulin)

• Rarely, pancreatitis or lactic acidosis (linked to Metformin)

Precautions and Warnings

• Monitor renal and hepatic function regularly

• Maintain adequate hydration during Metformin therapy to reduce risk of lactic acidosis

• Discontinue Metformin temporarily in patients undergoing radiologic studies with contrast agents

• Use with caution in patients with a history of hypersensitivity or pancreatitis

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Drug Interactions

• Linagliptin has minimal CYP-mediated interactions, but caution is advised when combined with strong CYP3A4 inducers or inhibitors

• Metformin may interact with cimetidine, diuretics, or contrast media affecting renal clearance

Pregnancy and Lactation

• Pregnancy: Category B for Linagliptin; Metformin may be used under medical supervision

• Lactation: Caution advised; excretion in breast milk is unknown

Storage Conditions

Store in a cool, dry place below 30°C, away from light and moisture. Keep out of reach of children.

Mode of Action

Linatab M combines:

• Linagliptin: Enhances incretin hormone activity, improving insulin release and reducing glucagon levels

• Metformin: Reduces liver glucose production and improves peripheral glucose uptake

Together, they provide complementary control of blood glucose, effectively managing type 2 diabetes when monotherapy is insufficient.